Prevalence of focal atrial fibrillation in the “Ablate and Pace” patient population

EP Europace ◽  
2001 ◽  
Vol 2 ◽  
pp. A6-A6
Keyword(s):  
Atrial Fibrillation ◽  
Patient Population

scholarly journals Prevalence of focal atrial fibrillation in the “Ablate and Pace” patient population

EP Europace ◽  
2001 ◽  
Vol 2 (Supplement_1) ◽  
pp. A6-A6
Author(s):  
R. Verlato ◽  
P. Turrini ◽  
S. Baccillieri ◽  
J. Arango-Cifuentes ◽  
F. Campisi ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Patient Population

Risk Factors for Bleeding in Patients with Nonvalvular Atrial Fibrillation Who Are Receiving Anticoagulant Therapy with Ximelagatran or Warfarin: Findings from the SPORTIF III and V Trials.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 528-528
Author(s):  
James D. Douketis ◽  
Karin Arneklev ◽  
Samuel Goldhaber ◽  
John Spandorfer ◽  
Frank Halperin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Atrial Fibrillation ◽  
Major Bleeding ◽  
Patient Population ◽  
Left Ventricular ◽  
Nonvalvular Atrial Fibrillation ◽  
Increased Risk ◽  
Risk For Bleeding ◽  
Statin Use

Abstract Background: Ximelagatran is a novel oral direct thrombin inhibitor that is as effective as warfarin in preventing stroke and other thromboembolic complications in patients with nonvalvular atrial fibrillation (AF). Risk factors for bleeding with warfarin are known, but risk factors for bleeding with ximelagatran have not been described. Unlike warfarin, ximelagatran has a predictable anticoagulant effect, does not require anticoagulation monitoring, has a low potential for interactions with drugs, food, or alcohol, and is not affected by genetic polymorphisms. We undertook an exploratory analysis of a large patient database to identify conventional and novel risk factors for bleeding in ximelagatran-treated patients, in warfarin-treated patients, and in all patients, irrespective of treatment. Methods: We undertook a pooled analysis of the SPORTIF III and V trials trials, which included 7329 patients with nonvalvular AF who received oral ximelagatran, 36 mg twice daily, or warfarin, administered to achieve a target international normalized ratio of 2.0–3.0. Patients had nonvalvular AF and 1 or more risk factors for stroke: hypertension; age ≥75 years; previous stroke, transient ischemic attack (TIA) or systemic embolism; left ventricular dysfunction; age ≥65 years and coronary artery disease; or age ≥65 years and diabetes mellitus. Major exclusion criteria were: mitral stenosis; previous heart valve surgery; transient AF; increased risk for bleeding. Multivariate logistic regression analysis was used to identify independent risk factors for major bleeding. The hazard ratio (HR) for major bleeding, and corresponding 95% confidence interval (CI), was calculated for each variable in the regression model. Results: The Table presents risk factors in which there was a significant or a non-significant (NS) association with major bleeding in ximelagatran-treated or warfarin-treated patients, and in the combined patient population. Risk factor Ximelagatran-treated patients, HR (95% CI) Warfarin-treated patients, HR (95% CI) Combined patient population, HR (95% CI) Aspirin use 1.65 (1.07, 2.55) 2.40 (1.69, 3.42) 1.96 (1.49, 2.58) Increasing age 1.03 (1.01, 1.05) 1.06 (1.03, 1.08) 1.04 (1.03, 1.06) Prior liver disease NS 4.96 (1.57, 15.62) NS Prior stroke or TIA 1.78 (1.16, 2.73) NS NS Diabetes mellitus 1.80 (1.18, 2.75) NS 1.39 (1.05, 1.86) Asian race NS NS 1.99 (1.16, 3.42) Statin use 0.62 (0.39, 0.97) 0.61 (0.42, 0.88) 0.62 (0.39, 0.97) Conclusions: Overall, the bleeding risk was lower with ximelagatran compared with warfarin. Aspirin use and increasing age were associated with an increased risk of bleeding in both ximelagatran- and warfarin-treated patients. Statin use was associated with a decreased risk for bleeding in both groups.

Long-term prognosis of de novo atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategies

2020 ◽  
Author(s):  
Felix Hofer ◽  
Niema Kazem ◽  
Andreas Hammer ◽  
Feras El-Hamid ◽  
Lorenz Koller ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Atrial Fibrillation ◽  
Acute Myocardial Infarction ◽  
Cardiovascular Mortality ◽  
Patient Population ◽  
De Novo ◽  
Treatment Strategies ◽  
Increased Risk ◽  
The Impact

Abstract Aims While the prognosis of patients presenting with de novo atrial fibrillation (AF) during the acute phase of myocardial infarction has been controversially discussed, it seems intuitive that affected individuals have an increased risk for both thrombo-embolic events and mortality. However, profound data on long-term outcome of this highly vulnerable patient population are not available in current literature. Therefore, we aimed to investigate the impact of de novo AF and associated anti-thrombotic treatment strategies on the patient outcome from a long-term perspective. Methods and results Patients presenting with acute myocardial infarction, treated at the Medical University of Vienna, were enrolled within a clinical registry and screened for the development of de novo AF. After discharge, participants were followed prospectively over a median time of 8.6 years. Primary study endpoint was defined as cardiovascular mortality. Out of 1372 enrolled individuals 149 (10.9%) developed de novo AF during the acute phase of acute myocardial infarction. After a median follow-up time of 8.6 years, a total of 418 (30.5%) died due to cardiovascular causes, including 93 (62.4%) in the de novo AF subgroup. We found that de novo AF was significantly associated with long-term cardiovascular mortality with an adjusted HR of 1.45 (95% CI 1.19–2.57; P < 0.001). While patients with de novo AF were less likely to receive a triple anti-thrombotic therapy as compared to patients with pre-existing AF at time of discharge, this therapeutic approach showed a strong and inverse association with mortality in de novo AF, with an adj. HR of 0.86 (95% CI 0.45–0.92; P = 0.012). Conclusion De novo AF was independently associated with a poor prognosis with a 67% increased risk of long-term cardiovascular mortality. Intensified anti-thrombotic treatment in this high-risk patient population might be considered.

scholarly journals DIAGNOSIS-TO-ABLATION TIME PREDICTS ATRIAL FIBRILLATION SUCCESS IN A HIGH-RISK PATIENT POPULATION

2021 ◽  
Vol 77 (18) ◽  
pp. 322
Author(s):  
Mark Brahier ◽  
Fengwei Zou ◽  
Frank Migliarese ◽  
Alexandra Taylor ◽  
Athanasios Thomaides ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
High Risk ◽  
Patient Population ◽  
High Risk Patient ◽  
Risk Patient ◽  
Ablation Time

scholarly journals The Convergent Procedure – A Standardised and Anatomic Approach Addresses the Clinical and Economic Unmet Needs of the Persistent Atrial Fibrillation Population

2013 ◽  
Vol 2 (2) ◽  
pp. 145 ◽  
Author(s):  
James McKinnie ◽  
Keyword(s):  
Atrial Fibrillation ◽  
Treatment Option ◽  
Patient Population ◽  
Treatment Options ◽  
Structural Heart Disease ◽  
Persistent Atrial Fibrillation ◽  
Posterior Wall ◽  
Management Approach ◽  
Success Rates

A standardised treatment management approach is needed to address the escalating worldwide prevalence of atrial fibrillation (AF). The persistent and longstanding persistent AF patient population particularly needs this standardised treatment option to manage their AF. These patients have underlying structural heart disease that result in increased hospitalizations, long-term medical management that increases the cost burden of the healthcare system. Approximately 100 patients have undergone the Convergent Procedure at our center since its introduction 2 years ago, as a treatment option for AF patients. The epicardial and endocardial ablation procedures performed sequentially in a single setting has shown a single procedure success rate of 80%, similar to published success rates at other centers. The epicardial posterior wall isolation silences a majority of known substrates and the endocardial procedure completes the pulmonary vein isolation, creates the cavotricuspid line and provides diagnostic confirmation. The Convergent Procedure should be considered as a first line treatment option for the persistent and longstanding persistent AF patient population who have very limited or no treatment options for the long-term successful management of their AF.

scholarly journals Description of atrial fibrillation patient population with a dual chamber pacemaker

EP Europace ◽  
2001 ◽  
Vol 2 (Supplement_1) ◽  
pp. A20-A20 ◽  
Author(s):  
M. Jarwe ◽  
D. Klug ◽  
R. Carlioz ◽  
O. Thomas ◽  
P. Graux ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Patient Population ◽  
Atrial Fibrillation Patient ◽  
Dual Chamber ◽  
Dual Chamber Pacemaker

Ibutilide for rapid conversion of atrial fibrillation or flutter in a mixed critically ill patient population

2005 ◽  
Vol 117 (3) ◽  
pp. 92-97 ◽  
Author(s):  
Georg Delle Karth ◽  
Martin Schillinger ◽  
Alexander Geppert ◽  
Markus Haumer ◽  
Marianne Gwechenberger ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Critically Ill ◽  
Patient Population ◽  
Critically Ill Patient ◽  
Rapid Conversion

scholarly journals Budget impact analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients

2014 ◽  
Vol 15 (1S) ◽  
pp. 5-14
Author(s):  
Lorenzo Pradelli ◽  
Mario Calandriello ◽  
Roberto Di Virgilio ◽  
Marco Bellone ◽  
Marco Tubaro
Keyword(s):  
Atrial Fibrillation ◽  
Patient Population ◽  
Impact Analysis ◽  
Budget Impact ◽  
Health Care Expenditure ◽  
Indirect Comparison ◽  
Budget Impact Analysis ◽  
Experimental Population ◽  
Italian Population ◽  
Treatment Comparison

OBJECTIVE: This study aims to perform a budget impact analysis of the use of three available novel oral anticoagulant agents (NOACs) for preventing thromboembolic events in Italian patients with non‑valvular atrial fibrillation (NVAF).METHODS: Estimated Italian population of patients was run through a previously published lifetime decision tree/Markov model simulating their treatment with the available therapeutic options: dabigatran at two dose levels (110 mg/bid for the over 80 years old, 150 mg/bid for younger NVAF patients), rivaroxaban (20 mg/uid), and apixaban (5 mg/bid). Effectiveness and safety estimates derive from an adjusted indirect treatment comparison using warfarin as link. The main clinical events considered in the model are ischemic and hemorrhagic stroke, systemic thromboembolism, bleeds (both major and clinically relevant minor) and cardiovascular hospitalizations, besides treatment discontinuations. Epidemiological data and unit costs, actualized to 2013, are collected from Italian published sources. The budget impact analysis evaluates the financial impact of apixaban introduction by comparing expected 1,2, and 3 years costs in hypothetical scenarios: with and without apixaban. Italian NVAF patient population estimation is based on official apixaban reimbursement criteria, applying the characteristics of the trial population to national epidemiologic data. Numbers of patients for each regimen are estimated by projecting share evolution. Sensitivity analysis is performed on an alternative non‑experimental population of NVAF patients.RESULTS: Among available NOACs, apixaban was expected to be the least expensive in an estimated patient population of 364,000 Italian patients, allowing for savings of € 1,180,549, € 3,841,429 and € 5,368,918 at 1,2, and 3 years, respectively. Results of the simulation run on an alternative non‑experimental population of NVAF patients yields comparable estimates.CONCLUSIONS: The different safety and effectiveness profiles of the three available NOACs emerging from the adjusted indirect comparison indicate that apixaban could improve health care expenditure control while maintaining or increasing therapeutic appropriateness in the Italian NVAF population.

Sign in / Sign up

Export Citation Format

Share Document